Remove 2019 Remove Individual Remove Medical Remove Provider
article thumbnail

Differences in primary care utilization by primary care availability in the first year of Virginia Medicaid Expansion [Health care disparities]

Annals of Family Medicine

Importantly, Virginia's Medicaid expansion reduced cost-related barriers to accessing care for over 700,000 individuals. Setting or Dataset: 2019-2020 Virginia Department of Medical Assistance Services database (demographic, enrollment, and claims data). Of these, 117,481 (57.2%) individuals had at least one primary care visit.

article thumbnail

National variation in ASCVD risk between Pooled Cohort Equations and PREVENT [Cardiovascular disease]

Annals of Family Medicine

Context In November 2023, the American Heart Association (AHA) released PREVENT, a new set of risk equations to calculate an individual's risk of atherosclerotic cardiovascular disease (ASCVD). Each individual was separated into clinically significant risk categories of <7.5%, 7.5-10%, Results 3,885 individuals met the criteria.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Episode 282: Anti-Racism in Medicine Series – Episode 20 – Medical Racism and Indigenous Peoples

The Clinical Problem Solvers

[link] CPSolvers: Anti-Racism in Medicine Series Episode 20 – Medical Racism and Indigenous Peoples Show Notes by Sudarshan (“Sud”) Krishnamurthy April 4, 2023 Summary: This episode highlights the checkered past of medicine and the advancements in the field that have occurred at the expense of the humanity of Indigenous peoples.

Medical 52
article thumbnail

Let’s Listen to Patients: FDA Releases Final Guidance on Patient Engagement in the Design and Conduct of Medical Device Clinical Studies

FDA Law

Bauer, Senior Regulatory Drug Expert — Our readers probably know that we value and advocate for patient engagement as an essential component in the development of medical products (see our firm’s commitment here ). The Guidance provides practical advice for device manufacturers to utilize patient engagement in clinical studies.

article thumbnail

Approaches for Quelling Stigma related to COVID-19

BMJ

A multilayered view of stigmatizing discourses lays the foundation for eliciting a series of suggestions for quelling stigma, to be implemented at the individual, community, and national levels, as suggested by the WHO. Psychological health during the coronavirus disease 2019 pandemic outbreak. Scholars such as Wen et al.

article thumbnail

Long-Awaited Guidance on FDAMA 115: Confirmatory Evidence Finally Has Its Moment (to be Crossed Off the FDA’s Guidance To-Do List)

FDA Law

A brief explainer on confirmatory evidence: how we got here Before we dive into the specifics of the new guidance, we should explain that the statutory standard we allude to is the requirement that an applicant provide “substantial evidence of effectiveness” to obtain approval of an NDA or BLA.

IT 64
article thumbnail

The Incredible Shrinking Exemption: FDA Final CDS Guidance Would Significantly Narrow the Scope of Exempt Clinical Decision Support Software Under the Cures Act

FDA Law

Javitt — On September 28, 2022, the FDA issued the long anticipated final Clinical Decision Support Software Guidance (CDS Guidance), which replaces the revised draft guidance document from 2019. Criterion 2 : Non-Device CDS software functions display, analyze or print medical information about a patient or other medical information.

Clinic 52